Lisa's experience with a pharmaceutical cGMP approach in a regulated environment is a critical skill set as the industry we serve continues to mature into a commercial one
Hackensack, NJ (PRWEB) March 17, 2009
Progenitor Cell Therapy, LLC (PCT) today announced that Lisa Doria-Cavuoto will be joining the company as Vice President of Commercial Cell Therapies, effective April 1, 2009. In this role, she will be responsible for managing the day-to-day business operations of PCT's commercial stem cell processing, storage, and clinical distribution service.
Ms. Doria-Cavuoto has approximately 20 years of professional experience with a primary focus in the life sciences, healthcare and pharmaceutical sectors. Previous to this appointment, Ms. Doria-Cavuoto was a principal of LDC Consulting, LLC where she provided strategic and tactical consultation and project management services to the pharmaceutical industry.
Prior positions include Director of Clinical Services for PCT, Clinical Care Coordinator of the Stem Cell Transplant Program at Hackensack University Medical Center as well as Product Manager for Aventis Oncology and an account supervisor for the McCann Healthcare Worldwide Company.
A graduate of Creighton University, Ms. Doria-Cavuoto is a registered nurse who also received a Masters of Public Administration in Executive Healthcare Management from Fairleigh Dickinson University.
"We are very pleased to add someone with Lisa's background and experience to our senior management team," states PCT Chief Executive Officer, Dr. Andrew L. Pecora. "PCT continues to make great strides in executing our growth strategy with the expansion of our stem cell product offerings and Lisa will have a major role in assisting us with the achievement of our objectives".
"With the addition of Lisa to our management team, we continue to enhance the commercial quality of our comprehensive offering to the cell therapy community", states PCT President and Chief Scientific Officer, Dr. Robert A. Preti. "Lisa's experience with a pharmaceutical cGMP approach in a regulated environment is a critical skill set as the industry we serve continues to mature into a commercial one".
About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit http://www.progenitorcelltherapy.com.
John P. Gandolfo, Chief Financial Officer
This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "intend," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue" or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.